nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
Lung Cancer (Auckl)
nab-paclitaxel; non-small cell lung cancer; quality of life; response; squamous
Background: Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, receiving ≤4 cycles of
Methods: Patients received
Results: Two-hundred and six lesion-response-evaluable patients completed baseline + ≥1 postbaseline QoL assessment and were QoL evaluable. LCSS average total score and symptom burden index improved from baseline throughout four cycles. In the LCSS pulmonary symptoms score, 46% of patients reported clinically meaningful improvement (≥10 mm visual analog scale) from baseline. Individual EQ-5D-5L dimensions remained stable/improved in ≥83% of patients; ≈33% reported complete resolution of baseline problems at least once during four cycles. Generally, responders (unconfirmed complete/partial response) had higher scores vs nonresponders.
Conclusion: In patients with squamous NSCLC, four cycles of
Thomas, Michael; Spigel, David R; Jotte, Robert M; McCleod, Michael; Socinski, Mark A; Page, Ray D; Gressot, Laurent; Knoble, Jeanna; Juan, Oscar; Morgensztern, Daniel; Isla, Dolores; Kim, Edward S; West, Howard; Ko, Amy; Ong, Teng Jin; Trunova, Nataliya; and Gridelli, Cesare, "nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy" (2017). Articles, Abstracts, and Reports. 1479.